Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921241 | 1.00 | KCNH2 (0.42) | KCNH2KMOTSHRHTTMEN1 | |
| SCHEMBL921531 | 0.90 | KCNH2 (0.42) | KCNH2KMOTSHRHTTMEN1 | |
| SCHEMBL706370 | 0.87 | KCNH2 (0.40) | KCNH2KMOTSHRHTTMEN1 | |
| SCHEMBL706371 | 0.85 | KCNH2 (0.42) | KCNH2KMOTSHRHTTMEN1 | |
| SCHEMBL708389 | 0.85 | KCNH2 (0.42) | KCNH2KMOTSHRHTTMEN1 | |
| SCHEMBL921877 | 0.83 | KCNH2 (0.39) | KCNH2KMOTSHRHTTMEN1 | |
| SCHEMBL704085 | 0.81 | KCNH2 (0.47) | KCNH2KMOTSHRHTTMEN1 | |
| SCHEMBL704086 | 0.81 | KCNH2 (0.47) | KCNH2KMOTSHRHTTMEN1 | |
| SCHEMBL706101 | 0.78 | KCNH2 (0.40) | KCNH2KMOTSHRHTTMEN1 | |
| SCHEMBL1526206 | 0.77 | KCNH2 (0.69) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885KMO 2826/4885TSHR 4850/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885KMO 2826/4885TSHR 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.